查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1618841

粒子治療市場：按治療類型、成分、成分、癌症類型、最終用戶 - 2025-2030 年全球預測

Particle Therapy Market by Therapy Type (Heavy Ion Therapy, Proton Therapy), Component (Product, Service), Configuration, Cancer Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年粒子治療市值為7.7241億美元，預計到2024年將達到8.315億美元，複合年成長率為7.94%，到2030年將達到13.1887億美元。

粒子療法主要包括質子療法和重離子療法，是一種利用帶電粒子進行癌症治療的外束放射療法。它能夠精確地瞄準腫瘤，同時最大限度地減少對周圍健康組織的損害，從而減少了與傳統放射治療相關的副作用，滿足了癌症治療的關鍵需求。它已應用於多種癌症，包括兒童癌症、前列腺癌和頭頸癌，並且在眼部腫瘤和神經系統疾病的治療中變得越來越效用。主要的最終用途部分是醫療設施，例如專科醫院和癌症治療中心。

主要市場統計
基準年[2023] 77241萬美元
預計年份 [2024] 8.315 億美元
預測年份 [2030] 1,318.87 百萬美元
複合年成長率（%） 7.94%

市場成長的推動因素包括治療系統的技術進步、癌症發生率的增加、對先進治療方案認知的提高以及政府的支持措施。筆射束掃描和調變質子治療的最新創新提高了治療精度，並為投資研發的公司創造了有利可圖的機會。然而，高安裝和營運成本、有限的設施可用性以及複雜的監管核准等挑戰正在阻礙市場擴張。此外，缺乏熟練的專業人員是開發中地區的一個主要障礙。

鼓勵希望利用成長機會的公司投資具有成本效益的技術，並與醫療保健提供者建立合作夥伴關係以建立新的治療中心。此外，擴大培訓計劃並擴展到尚未開發的新興市場可以促進更廣泛地獲得和採用粒子療法。

由於專注於改善臨床結果和減輕患者和醫療保健提供者的經濟負擔的技術創新，粒子治療市場仍然具有競爭力。專注於開發混合治療解決方案以及將人工智慧融入個人化治療計劃的公司將保持在該行業的前沿。儘管存在經濟和物流方面的限制，但在持續的研發努力以及支持先進癌症治療的不斷發展的監管環境的支持下，市場軌跡仍然充滿希望。這些進步有望重塑治療模式並擴大粒子治療在全球的應用潛力。

市場動態：揭示快速發展的粒子治療市場的關鍵市場洞察

供需的動態交互作用正在改變粒子治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 癌症治療需要先進的治療方法
    • 在臨床測試中擴大採用粒子束療法
    • 世界各地粒子治療中心的增加
  • 市場限制因素
    • 粒子束治療設備和程序高成本，粒子束治療的保險範圍有限
  • 市場機會
    • 正在進行的質子治療研究計劃
    • 帶電粒子束治療的技術進步和個人化癌症治療策略的實現
  • 市場問題
    • 與粒子束治療輻射暴露相關的風險

波特五力：引領粒子治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解粒子治療市場的外部影響

外部宏觀環境因素在塑造粒子治療市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解粒子束治療市場的競爭格局

對粒子治療市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：粒子治療市場供應商績效評估

FPNV定位矩陣是評估粒子治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製粒子治療市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，粒子束治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開發：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、未開發地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症治療需要先進的治療方法
      • 在臨床測試中更多地採用粒子束療法
      • 世界各地的粒子治療中心不斷增加
    • 抑制因素
      • 粒子治療設備和程序的成本很高，而且粒子治療的保險範圍有限。
    • 機會
      • 正在進行的質子治療調查計畫
      • 帶電粒子束治療的技術進步和個人化癌症治療策略的實現
    • 任務
      • 與粒子束治療輻射暴露相關的風險
  • 市場區隔分析
    • 治療類型：消費者更喜歡質子治療，因為對周圍組織損傷的風險較低
    • 組件：高精度增加了產品組件的使用，以治療重要器官附近的固態腫瘤
    • 配置：可以同時治療多個患者的多房間系統的可能性
    • 癌症類型：由於降低了健康組織的風險，粒子療法在頭頸癌的應用不斷擴大
    • 最終使用者：粒子治療在醫院和醫療機構致力於提供高品質護理方面發揮重要作用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章粒子治療市場：依治療類型

  • 介紹
  • 重粒子線治療
  • 質子治療

第7章粒子治療市場：依組成部分

  • 介紹
  • 產品
    • 迴旋加速器
    • 同步迴旋加速器
    • 同步加速器
  • 服務

第8章粒子治療市場：依成分分類

  • 介紹
  • 多房間系統
  • 單間系統

第9章粒子束治療市場：依癌症類型

  • 介紹
  • 乳癌
  • 頭頸癌
  • 肺癌
  • 兒童癌症
  • 攝護腺癌

第 10 章 粒子治療市場：依最終使用者分類

  • 介紹
  • 門診手術中心
  • 醫院/診所

第11章 美洲粒子治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太粒子治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的粒子治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • IBA 與 PARTICLE 啟動 FLASH 質子治療研究夥伴關係
    • P-Cure 獲得 FDA核准用於坐位治療的質子治療系統，並開始在以色列治療患者
    • Terapet 籌集了 230 萬瑞士法郎用於下一代癌症治療技術
  • 戰略分析和建議

公司名單

  • Advanced Oncotherapy plc
  • B dot Medical Inc.
  • Best Particle Therapy, Inc.
  • BioSig Technologies Inc.
  • Covenant Health
  • Danfysik A/S
  • Elekta AB
  • Hitachi, Ltd.
  • IBA International
  • Koninklijke Philips NV
  • Mevion Medical Systems
  • Mitsubishi Electric Corporation
  • New Mexico Cancer Center
  • Optivus Proton Therapy, Inc.
  • P-Cure Ltd
  • ProTom International
  • Provision Healthcare, LLC
  • PTW Freiburg GmbH
  • SAH Global LLC
  • Shanghai APACTRON Particle Equipment Co., Ltd.
  • Siemens Healthineers GmbH
  • Stantec Inc.
  • Sumitomo Heavy Industries, Ltd.
  • Toshiba Medical Systems Corporation
  • Xstrahl Ltd.
Product Code: MRR-335201F2E2B6

The Particle Therapy Market was valued at USD 772.41 million in 2023, expected to reach USD 831.50 million in 2024, and is projected to grow at a CAGR of 7.94%, to USD 1,318.87 million by 2030.

Particle therapy, primarily comprising proton and heavy ion therapy, is a form of external beam radiotherapy utilizing charged particles for cancer treatment. Due to its precision in targeting tumors while minimizing damage to surrounding healthy tissues, it addresses a critical necessity in cancer treatment, reducing side effects associated with conventional radiation therapy. Applications span a variety of cancers, including pediatric, prostate, and head and neck cancers, with growing utility in treating ocular tumors and neurological disorders. End-use sectors primarily include healthcare facilities like specialized hospitals and cancer treatment centers.

KEY MARKET STATISTICS
Base Year [2023] USD 772.41 million
Estimated Year [2024] USD 831.50 million
Forecast Year [2030] USD 1,318.87 million
CAGR (%) 7.94%

Market growth is driven by technological advancements in treatment delivery systems, increasing incidence of cancer, rising awareness about advanced treatment options, and supportive government initiatives. Recent innovations in pencil beam scanning and intensity-modulated proton therapy have heightened treatment accuracy, presenting lucrative opportunities for companies investing in R&D. However, challenges such as high installation and operational costs, limited availability of facilities, and intricate regulatory approvals constrain market expansion. Additionally, the lack of skilled professionals poses a significant barrier in developing regions.

For businesses aiming to capitalize on growth opportunities, investing in cost-effective technologies and building collaborations with healthcare providers to establish new treatment centers are recommended. Furthermore, enhancing training programs and expanding into untapped emerging markets could foster broader accessibility and adoption of particle therapy.

The particle therapy market remains competitive, with innovation centered on improving clinical outcomes and reducing financial burdens for patients and providers. Companies focusing on developing hybrid therapy solutions and integrating AI for personalized treatment planning can stay at the forefront of the industry. Despite financial and logistical constraints, the market's trajectory remains promising, bolstered by continuous R&D efforts and evolving regulatory landscapes favoring advanced cancer therapies. Such advancements promise to reshape treatment paradigms and expand the potential for particle therapy applications worldwide.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Particle Therapy Market

The Particle Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Need for advanced therapies in cancer treatment
    • Rise in adoption of particle therapy in clinical trials
    • Growing number of particle therapy centers worldwide
  • Market Restraints
    • High cost of particle therapy equipment and procedures, along with limited insurance coverage for particle therapy
  • Market Opportunities
    • Ongoing proton therapy research programs
    • Technological advances in charged-particle therapy and enabling personalized cancer treatment strategies
  • Market Challenges
    • Risk associated with the particle therapy radiation exposure

Porter's Five Forces: A Strategic Tool for Navigating the Particle Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Particle Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Particle Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Particle Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Particle Therapy Market

A detailed market share analysis in the Particle Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Particle Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Particle Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Particle Therapy Market

A strategic analysis of the Particle Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Particle Therapy Market, highlighting leading vendors and their innovative profiles. These include Advanced Oncotherapy plc, B dot Medical Inc., Best Particle Therapy, Inc., BioSig Technologies Inc., Covenant Health, Danfysik A/S, Elekta AB, Hitachi, Ltd., IBA International, Koninklijke Philips N.V., Mevion Medical Systems, Mitsubishi Electric Corporation, New Mexico Cancer Center, Optivus Proton Therapy, Inc., P-Cure Ltd, ProTom International, Provision Healthcare, LLC, PTW Freiburg GmbH, SAH Global LLC, Shanghai APACTRON Particle Equipment Co., Ltd., Siemens Healthineers GmbH, Stantec Inc., Sumitomo Heavy Industries, Ltd., Toshiba Medical Systems Corporation, and Xstrahl Ltd..

Market Segmentation & Coverage

This research report categorizes the Particle Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Therapy Type, market is studied across Heavy Ion Therapy and Proton Therapy.
  • Based on Component, market is studied across Product and Service. The Product is further studied across Cyclotrons, Synchrocyclotrons, and Synchrotrons.
  • Based on Configuration, market is studied across Multi-room System and Single-room System.
  • Based on Cancer Type, market is studied across Breast Cancer, Head & Neck Cancer, Lung Cancer, Pediatric Cancer, and Prostate Cancer.
  • Based on End-User, market is studied across Ambulatory Surgery Centers and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Need for advanced therapies in cancer treatment
      • 5.1.1.2. Rise in adoption of particle therapy in clinical trials
      • 5.1.1.3. Growing number of particle therapy centers worldwide
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of particle therapy equipment and procedures, along with limited insurance coverage for particle therapy
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing proton therapy research programs
      • 5.1.3.2. Technological advances in charged-particle therapy and enabling personalized cancer treatment strategies
    • 5.1.4. Challenges
      • 5.1.4.1. Risk associated with the particle therapy radiation exposure
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapy Type: Consumer preference for proton therapy as it provides a reduced risk of damage to surrounding tissues
    • 5.2.2. Component: Rising utilization of product components for treating solid tumors near vital organs due to their high accuracy
    • 5.2.3. Configuration: Potential of a multi-room system for treating a larger number of patients concurrently
    • 5.2.4. Cancer Type: Expanding usage of particle therapy for head & neck cancer owing to reduced risk on healthy tissue
    • 5.2.5. End-User: Significant role of particle therapy in hospitals & clinicals as they strive to provide high-quality care
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Particle Therapy Market, by Therapy Type

  • 6.1. Introduction
  • 6.2. Heavy Ion Therapy
  • 6.3. Proton Therapy

7. Particle Therapy Market, by Component

  • 7.1. Introduction
  • 7.2. Product
    • 7.2.1. Cyclotrons
    • 7.2.2. Synchrocyclotrons
    • 7.2.3. Synchrotrons
  • 7.3. Service

8. Particle Therapy Market, by Configuration

  • 8.1. Introduction
  • 8.2. Multi-room System
  • 8.3. Single-room System

9. Particle Therapy Market, by Cancer Type

  • 9.1. Introduction
  • 9.2. Breast Cancer
  • 9.3. Head & Neck Cancer
  • 9.4. Lung Cancer
  • 9.5. Pediatric Cancer
  • 9.6. Prostate Cancer

10. Particle Therapy Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgery Centers
  • 10.3. Hospitals & Clinics

11. Americas Particle Therapy Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Particle Therapy Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Particle Therapy Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. IBA and PARTICLE Initiate FLASH Proton Therapy Research Partnership
    • 14.3.2. P-Cure Receives FDA Approval For Proton Therapy System For Treatment in Seated Position and Will Begin Treating Patients In Israel
    • 14.3.3. Terapet raises CHF 2.3 million for its next-generation cancer treatment technology
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Advanced Oncotherapy plc
  • 2. B dot Medical Inc.
  • 3. Best Particle Therapy, Inc.
  • 4. BioSig Technologies Inc.
  • 5. Covenant Health
  • 6. Danfysik A/S
  • 7. Elekta AB
  • 8. Hitachi, Ltd.
  • 9. IBA International
  • 10. Koninklijke Philips N.V.
  • 11. Mevion Medical Systems
  • 12. Mitsubishi Electric Corporation
  • 13. New Mexico Cancer Center
  • 14. Optivus Proton Therapy, Inc.
  • 15. P-Cure Ltd
  • 16. ProTom International
  • 17. Provision Healthcare, LLC
  • 18. PTW Freiburg GmbH
  • 19. SAH Global LLC
  • 20. Shanghai APACTRON Particle Equipment Co., Ltd.
  • 21. Siemens Healthineers GmbH
  • 22. Stantec Inc.
  • 23. Sumitomo Heavy Industries, Ltd.
  • 24. Toshiba Medical Systems Corporation
  • 25. Xstrahl Ltd.

LIST OF FIGURES

  • FIGURE 1. PARTICLE THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. PARTICLE THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PARTICLE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PARTICLE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. PARTICLE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. PARTICLE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PARTICLE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PARTICLE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PARTICLE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PARTICLE THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HEAVY ION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PROTON THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CYCLOTRONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SYNCHROCYCLOTRONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SYNCHROTRONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SERVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PARTICLE THERAPY MARKET SIZE, BY MULTI-ROOM SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PARTICLE THERAPY MARKET SIZE, BY SINGLE-ROOM SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PARTICLE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PARTICLE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PEDIATRIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PARTICLE THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PARTICLE THERAPY MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL PARTICLE THERAPY MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES PARTICLE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. INDONESIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. JAPAN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. TAIWAN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. THAILAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. VIETNAM PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA PARTICLE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 153. DENMARK PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 159. EGYPT PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. FINLAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 171. FRANCE PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. GERMANY PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. ISRAEL PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. ITALY PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. NIGERIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 207. NORWAY PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. POLAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 219. QATAR PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. RUSSIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 231. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. SPAIN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 249. SWEDEN PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 261. TURKEY PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY CONFIGURATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM PARTICLE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 279. PARTICLE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 280. PARTICLE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023